AI Labs Group S.L.
Bilbao, Basque Country, 48001, Spain
NCT Number: NCT07428941
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions. Skin issues are a frequent reason for doctor visits, but differences in expertise between general practitioners and specialists can sometimes lead to misdiagnoses or unnecessary referrals.
The researchers hypothesized that the information provided by the AI device would increase the true diagnostic accuracy of primary care practitioners for multiple dermatological conditions. To test this, the study followed a prospective, self-controlled design where each participating doctor served as their own comparison.
During the study, 9 primary care physicians evaluated 30 clinical images representing a variety of skin pathologies. For each image, the doctors followed a two-step process:
* First, they provided a diagnosis based only on the image and the patient's medical history. * Second, they were shown the AI's analysis-including the top 5 suggested diagnoses and confidence levels-and asked to provide a final diagnosis.
The study also investigated if the AI could help doctors decide whether a patient truly needs a referral to a specialist or if the condition could be handled remotely via teledermatology. The primary question was whether using this AI support would significantly increase the number of correct diagnoses made by primary care doctors and lead to more efficient patient care.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bilbao, Basque Country, 48001, Spain
This detailed description outlines the clinical methodology, technical framework, and data integrity protocols utilized in the investigation of the Legit Health Plus medical device for skin pathologies in primary care.
Study Design and Technical Methodology The research was conducted as a prospective observational and cross-sectional self-controlled study. It utilized a Multi-Reader Multi-Case (MRMC) framework to measure the impact of Computer-Aided Diagnosis (CAD) on clinician performance.
Quality Assurance and Data Management
To ensure the scientific integrity of the clinical investigation, the following quality and monitoring protocols were implemented:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention consists of a Computer-Aided Diagnosis (CAD) software-only medical device that utilizes computer vision algorithms to analyze digital images of skin structures. During the study, healthcare professionals use the tool as a diagnostic support system to assist in the evaluation of complex dermatological conditions.
Time frame: Day 1
This measure evaluates the "Top-1" diagnostic accuracy of primary care practitioners (PCPs). Accuracy is determined by comparing the clinician's identified diagnosis-both before and after receiving the AI's top 5 suggestions-against a confirmed reference standard (confirmed by dermatologists or anatomical pathology).
Time frame: Day 1
This outcome validates the percentage of cases that practitioners determine should be referred to a dermatology specialist after reviewing the AI-provided information, including malignancy indices and tool recommendations. The goal is to evaluate if the device helps optimize resource allocation by reducing unnecessary referrals
Time frame: Day 1
This measure assesses the practitioners' evaluation of whether a case can be confirmed and treated remotely through teledermatology based on the AI analysis. A Pearson's chi-squared test is used to analyze the association between referral necessity and remote consultation feasibility.
AI Labs Group S.L
Industry
A Multi-Reader Multi-Case (MRMC) Study Assessing the Impact of Legit.Health Plus on the Diagnostic Accuracy and Referral Decision-Making of Primary Care Physicians for Skin Lesions.
Acronym: LegitHealth PH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02056522
Melanoma, Neoplasms
Kiryat Bialik, Israel
View Trial DetailsNCT07349940
Melanoma, Melanoma In Situ
Brno, Czechia
View Trial DetailsNCT06731062
Skin Care, Skin Lesion
Itapevi, São Paulo, Brazil
View Trial DetailsNCT06663241
Skin Lesions
Fairborn, Ohio, United States
View Trial Details